Danielle A M Heideman
Overview
Explore the profile of Danielle A M Heideman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
5516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bell M, Baussano I, Rol M, Tenet V, Heideman D, Gheit T, et al.
J Clin Microbiol
. 2024 Dec;
63(2):e0140424.
PMID: 39723836
Despite first-void urine (FVU) being increasingly recognized as a credible specimen for human papillomavirus (HPV) detection, there is a lack of well-validated testing methods providing full quantitative genotyping required for...
2.
Verhoef L, Bleeker M, Polman N, Kroon K, Steenbergen R, Ebisch R, et al.
Int J Cancer
. 2024 Dec;
156(5):1065-1073.
PMID: 39686532
High-risk HPV (hrHPV)-based screening has led to many unnecessary colposcopy referrals, mainly because of direct referral after low-grade cytology (ASC-US/LSIL). DNA methylation and genotyping tests on ASC-US/LSIL samples have the...
3.
Liang L, Tanaka L, Radde K, Bussas U, Ikenberg H, Heideman D, et al.
BMC Infect Dis
. 2024 Sep;
24(1):1008.
PMID: 39300354
Background: A persisting high-risk human papillomavirus (HR-HPV) infection is causal for cervical cancer; however, there is limited population-based data on the prevalence of HPV infections in Germany. We assessed the...
4.
Louvanto K, Verhoef L, Pimenoff V, Eriksson T, Leppala S, Lagheden C, et al.
Int J Cancer
. 2024 May;
155(9):1549-1557.
PMID: 38801336
Cervical cancer screening programs, including triage tests, need redesigning as human papillomavirus (HPV)-vaccinated women are entering the programs. Methylation markers offer a potential solution to reduce false-positive rates by identifying...
5.
Kroon K, Bogaards J, Heideman D, Meijer C, Berkhof J
Cancer Epidemiol Biomarkers Prev
. 2024 Mar;
33(8):1037-1045.
PMID: 38546394
Background: High-risk human papillomavirus (hrHPV)-based cervical cancer screening in the Netherlands led to a substantial increase in number of colposcopy referrals and low-grade lesions detected. Genotyping strategies may be employed...
6.
Boni S, Tenet V, Horo A, Heideman D, Bleeker M, Tanon A, et al.
Int J Cancer
. 2023 Nov;
154(6):962-968.
PMID: 37942579
As human papillomavirus (HPV) immunisation and HPV-based cervical cancer (CC) screening programmes expand across sub-Saharan Africa, we investigated the potential impact of human immunodeficiency virus (HIV) status on high-risk (HR)-HPV...
7.
Thuijs N, van Beurden M, Duin S, Heideman D, Berkhof J, Steenbergen R, et al.
Histopathology
. 2023 Sep;
84(2):301-314.
PMID: 37726173
Aims: Adequate diagnosis of human papillomavirus (HPV)-associated high-grade squamous intraepithelial lesion (HSIL) and HPV-independent vulvar intraepithelial neoplasia (VIN) is essential but can be challenging. We comprehensively characterized a large population-based...
8.
Dick S, Heideman D, Mom C, Meijer C, Berkhof J, Steenbergen R, et al.
Int J Cancer
. 2023 Aug;
153(12):2011-2018.
PMID: 37539971
Women treated for CIN2/3 remain at increased risk of recurrent CIN and cervical cancer, and therefore posttreatment surveillance is recommended. This post hoc analysis evaluates the potential of methylation markers...
9.
Hognasbacka A, Poot A, Kooijman E, Schuit R, Schreurs M, Verlaan M, et al.
Nucl Med Biol
. 2023 May;
120-121:108349.
PMID: 37209556
Introduction: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that is able to inhibit the EGFR treatment resistance mutation T790M and primary EGFR mutations Del19 and L858R. The aim of...
10.
Sayinzoga F, Tenet V, Heideman D, Sibomana H, Umulisa M, Franceschi S, et al.
Lancet Glob Health
. 2023 May;
11(7):e1096-e1104.
PMID: 37207683
Background: Rwanda was the first African country to implement national human papillomavirus (HPV) vaccination (against types HPV6, 11, 16, and 18). In 2011, a school-based catch-up programme was initiated to...